Aller au contenu principal
Accès ouvert déclaré 2026 article

The Feasibility of Exosome-Enriched Platelet-rich Fibrin (PRF) for the Treatment of Gingival Recessions: A Case Series of 27 Patients.

1Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

PURPOSE: Given the emerging potential of bioactive, cell-free regenerative therapies, integrating exosomes into dental practice may provide a biologically driven, minimally invasive method to improve soft tissue healing and root coverage outcomes. Hence, this first case series aimed to clinically assess the efficacy and safety of exosome-enriched solid platelet-rich fibrin (Exos-solid-PRF) to treat gingival recessions. MATERIALS AND METHODS: Twenty-seven patients (125 teeth) treated between January 2023 and July 2024 using a minimally invasive vestibular access technique with Exos-solid-PRF and liquid-PRF were included. Autologous PRF was prepared via horizontal centrifugation and hydrated with exosomes before surgical application. Clinical parameters, such as attachment gain (AG), keratinized tissue (KT), recession depth (RD), and recession width (RW), were measured at baseline and at a 6-month follow-up. RESULTS: According to the Cairo classification system for recession, out of 125 teeth, 23 (18.4%) were recession type 1 (RT1) and 102 (81.6%) were RT2. Statistically significant improvements were observed in AG (+0.46 ± 0.84mm), RD (-1.93 ± 1.05 mm), and RW (-1.43 ± 1.43mm), with a mean root coverage of 68% and complete root coverage in 34 teeth. RT1 cases demonstrated 86% coverage, and RT2 cases achieved 64%, exhibiting the regenerative potential of this novel therapy in treating both isolated and multiple adjacent gingival recessions, particularly in the esthetic zone. CONCLUSIONS: While the outcomes for RT1 defects are comparable to those of gold-standard CTG approaches, the modest improvements in RT2 defects reflect both the potential and the limitations of this novel method. Additional controlled studies, long-term follow-up, and mechanistic investigations are required to validate these outcomes and optimize the therapeutic application of exosomes in clinical periodontology.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

La source scientifique ouverte est momentanément indisponible.

Les sujets associés

Periodontal Regeneration and TreatmentsOral microbiology and periodontitis researchExtracellular vesicles in disease

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.